It is no secret that
huge conflicts of interest exist between vaccine promoters and vaccine
makers. Pediatrician and vaccine developer Paul Offit, for example, who
is one of the nation’s leading promoters of mandatory use of government
recommended vaccines, holds a $1.5 million research chair at Children’s
Hospital in Philadelphia, funded in part by Merck.
Julie Gerberding left
her post as Director of the Centers for Disease Control and Prevention
(CDC), where she oversaw the creation of national vaccine policies, to
head Merck vaccines. Former Texas governor Rick Perry recommended
state-wide inoculation of all 11- and 12-year-old girls with Merck’s
Gardasil vaccine after his chief of staff left to work at Merck. Just as
disturbing are the millions of dollars that officials at the National
Institutes of Health (NIH) dole out to academic institutions and vaccine
manufacturers to improve vaccine technology, find new, lucrative
markets and boost vaccine marketability—functions that guarantee the
profitability of corporations, but do not always ensure the well being
of taxpayers, the public and patients. Today, taxpayer-supported
research to develop new drugs and vaccines is voraciously patented by
universities and drug companies for outsized Wall Street profits when
the research rightfully belongs to taxpayers. Development of the human
papillomavirus (HPV) Gardasil and Cervarix vaccines is a case in point.
The initial research was funded by the NIH, National Cancer Institute,
University of Rochester, Georgetown University and the University of
Queensland, which licensed them to Merck and GlaxoSmithKline. In 2015,
Merck made $1.9 billion on its Gardasil franchise.
|
No comments:
Post a Comment